



1 **Supplementary Figure S1. Experimental analysis of NDR1-mediated regulation of EMT and β -catenin pathway in prostate cancer cells.** A, B:
2 Migration and scratch assays demonstrate that NDR1 inhibits epithelial-mesenchymal transition (EMT) in prostate cancer cells (DU145) by reducing cell
3 migration and wound closure. C: Mutation of the NDR1 ATP-binding site (K118A) significantly reduces the phosphorylation rate of NDR1. D: Efficiency
4 verification of β -TrCP knockout, confirming successful elimination of β -TrCP protein. E-G: The gray value quantification for protein half-life experiments. H:
5 Immunoprecipitation (IP) with exogenous proteins confirms the direct interaction between FBXO11 and β -Catenin. I: IP with exogenous proteins confirms the
6 direct interaction between NDR1 and β -Catenin. J: IP with exogenous proteins confirms the direct interaction between NDR1 and FBXO11. K: Measurement
7 of panphosphorylation levels of IP-enriched FBXO11 reveals significant promotion of FBXO11 phosphorylation by NDR1. L: NDR1 promotes
8 phosphorylation of β -Catenin at residues S33/37. M: Changes in membrane expression of β -catenin after stimulation with TGF- β . N: Efficiency verification
9 of FBXO11 knockout, confirming successful down-expression of the FBXO11 protein. O: IP binding assay demonstrates that mutation of FBXO11 at residue
10 S187A affects its interaction with β -catenin.




- 13 **Supplementary Figure S2. Secondary mass spectrometry (MS/MS) spectrum of phosphorylated FBXO11 peptide.** Control Spectrum of Phosphorylated
 14 FBXO11 Peptide at (A) Serine 140 and 143, (B) Serine 147, (C) Serine 542, and (D) Serine 841.


A FBXO11 Ser140 Ser143 :VSGKSQDLAAAPAEQYLQEK (NC-FBXO11-293T)




B FBXO11 Ser147:VSGKSQDLAAAPAEQYLQEK (NC-FBXO11-293T)



C FBXO11 Ser542: GNSIFNGNQGGVYIFGDGR (NC-FBXO11-293T)




D FBXO11 Ser841: ISSYTSYPMHDFYR (NC-FBXO11-293T)




15
 16

17 **Supplementary Figure S3. Secondary mass spectrometry (MS/MS) spectrum of phosphorylated FBXO11 peptide with NDR1 co-expression.** Spectrum
 18 of phosphorylated FBXO11 peptide at (A) Serine 140 and 143, (B) Serine 147, (C) Serine 542, and (D) Serine 841 with NDR1 co-expression.

A FBXO11 Ser140 Ser143 :VSGKSQDLAAPAEQYLQEK (NDR1-FBXO11-293T)



21 **Supplementary Figure S4. Bioinformatics and experimental analyses of β -catenin and FBXO11 regulatory pathways.** A: Predicted post-translational
 22 modification sites of β -catenin. B: Conservation analysis of FBXO11 protein sequence across different species. C: Screening of small molecule activators for
 23 NDR1, showing the process of identifying compounds that enhance NDR1 activity as potential therapeutic agents. D: Prediction of FBXO11-mediated
 24 ubiquitination of β -catenin and PAK1, indicating the computational modeling of the interaction between FBXO11 and its substrates for ubiquitination, β -
 25 catenin, and PAK1.



26
 27

Supplementary Table S1. Sequences of primers used in RT-qPCR assay.

Gene Name		Primer sequences (5' to 3')
GAPDH	Forward	GAGTCAACGGATTGGTCGT
	primer	
	Reverse	GACAAGCTTCCCGTTCTCAG
	primer	
STK38	Forward	TCAGCACATGCTCGGAAGG
	primer	
	Reverse	ACAAGCCGTACCTCACCAAAT
	primer	
CTNNB1	Forward	CTTGGACTGAGACTGCTGATCTTG
	primer	
	Reverse	CACCAGAGTAAAAGAACGATAAGCTA
	primer	
STK38-K118A	Forward	TGTATGCAATGGCTATACTCCGTAAGCAGATATG
	primer	
	Reverse	GAGTATGCCATTGCATACACATGTCCGTATCTT
	primer	
FBXO11	Forward	TGGACGTGATGTTGGTGTTCACA
	primer	
	Reverse	TCCTCCAGTCTGCCCATGGTGA
	primer	
c-Myc	Forward	GGCTCCTGGCAAAAGGTCA
	primer	
	Reverse	CTGCGTAGTTGTGCTGATGT
	primer	
Cyclin D1	Forward	GCTGCGAAGTGGAAACCATC
	primer	
	Reverse	CCTCCTTCTGCACACATTGAA
	primer	
CTNNB1	Forward	GCGGTACCATGGCTACTCAAGCT
	primer	
	Reverse	CGGCCGCTCTAGACTCGAGTTA
	primer	
CTNNB1 S33A	Forward	CAGCAACAGTCTTACCTGGACGCTGGAATCCATTCT
	primer	
	Reverse	AGTGGCACAGAACATGGATTCCAGCGTCCAGGTAAGA
	primer	
CTNNB1 S37A	Forward	TACCTGGACTCTGGAATCCATGCTGGTGCCACTACC
	primer	
	Reverse	AGGAGCTGTGGTAGTGGCACCAAGCATGGATTCCAGA
	primer	

CTNNB1 S33A-	Forward	TACCTGGACGCTGGAATCCATGCTGGTGCCACTACC
S37A	primer	
	Reverse	AGGAGCTGTGGTAGTGGCACCAAGCATGGATTCCAGC
	primer	
CTNNB1 S1	Forward	GCGTCGACAAAAAGCGGCTGTT
	primer	
	Reverse	GCGTCTAGATTATGTGGCAAGTTCTGC
	primer	
CTNNB1 S2	Forward	CGTCGACAACGTGCAATCCCTGAA
	primer	
	Reverse	CGCGCGTAGATTAACTAGCCAGTATG
	primer	
CTNNB1 S3	Forward	CGTCGACAAGGTGGACCCCAAG
	primer	
	Reverse	CGCGCGTAGATTATACTGCCTCTGATAAC
	primer	
CTNNB1 S4	Forward	GC GGCGTCGACAAAATACCATTCCATT
	primer	
	Reverse	GGCGCGTAGATTACAGGTCAGTATCA
	primer	

28

29

30 **Supplementary Table S2. Correlation of NDR1 expression with prostate cancer characteristics.**

Characteristics	Low expression of	High expression of	p value
	NDR1	NDR1	
n	249	250	
T stage, n (%)			0.023
T2	109 (22.2%)	80 (16.3%)	
T3	133 (27%)	159 (32.3%)	
T4	4 (0.8%)	7 (1.4%)	
N stage, n (%)			0.047
N0	173 (40.6%)	174 (40.8%)	
N1	29 (6.8%)	50 (11.7%)	
M stage, n (%)			1.000
M0	221 (48.3%)	234 (51.1%)	
M1	1 (0.2%)	2 (0.4%)	
PSA (ng/ml), n (%)			0.136
< 4	208 (47.1%)	207 (46.8%)	
≥4	9 (2%)	18 (4.1%)	
Gleason score, n (%)			0.012
6	27 (5.4%)	19 (3.8%)	
7	132 (26.5%)	115 (23%)	
8	35 (7%)	29 (5.8%)	
9	55 (11%)	83 (16.6%)	
10	0 (0%)	4 (0.8%)	

31

32

33

34 **Supplementary Table 3. NetPhos3.1 predicts phosphorylation sites on FBXO11 by NDR1 (Score > 0.5).**

35

# Sequence	# x	Context	Score	Kinase	Answer
# AAV87312.1	3 S	--MNSVRAA	0.799	PKC	YES
#					
# AAV87312.1	15 S	PRRVSRPPR	0.998	unsp	YES
# AAV87312.1	15 S	PRRVSRPPR	0.834	PKB	YES
# AAV87312.1	15 S	PRRVSRPPR	0.788	PKA	YES
# AAV87312.1	15 S	PRRVSRPPR	0.530	PKC	YES
# AAV87312.1	15 S	PRRVSRPPR	0.510	RSK	YES
#					
# AAV87312.1	90 S	VAEESGPAGA	0.573	CKI	YES
#					
# AAV87312.1	97 S	GAQNSPYQL	0.837	unsp	YES
# AAV87312.1	97 S	GAQNSPYQL	0.583	cdk5	YES
# AAV87312.1	97 S	GAQNSPYQL	0.510	p38MAPK	YES
#					
# AAV87312.1	105 T	LRRKTLLPK	0.895	unsp	YES
# AAV87312.1	105 T	LRRKTLLPK	0.769	PKA	YES
# AAV87312.1	105 T	LRRKTLLPK	0.664	PKG	YES
#					
# AAV87312.1	111 T	LPKRTACPT	0.670	PKG	YES
# AAV87312.1	111 T	LPKRTACPT	0.536	unsp	YES
#					
# AAV87312.1	115 T	TACPTKNM	0.608	PKC	YES
#					
# AAV87312.1	118 S	PTKNSMEGA	0.758	unsp	YES
# AAV87312.1	118 S	PTKNSMEGA	0.577	cdc2	YES
#					
# AAV87312.1	123 S	MEGASTSTT	0.954	unsp	YES
#					
# AAV87312.1	124 T	EGASTSTTE	0.548	CKII	YES
#					
# AAV87312.1	125 S	GASTSTTEN	0.977	unsp	YES
# AAV87312.1	125 S	GASTSTTEN	0.537	CKI	YES
# AAV87312.1	125 S	GASTSTTEN	0.510	CKII	YES
#					
# AAV87312.1	140 S	RARVSGKSQ	0.998	unsp	YES
# AAV87312.1	140 S	RARVSGKSQ	0.849	PKC	YES
# AAV87312.1	140 S	RARVSGKSQ	0.738	PKA	YES
#					
# AAV87312.1	143 S	VSGKSQDLS	0.915	unsp	YES
#					
# AAV87312.1	147 S	SQDLAAAPA	0.626	unsp	YES
#					
# AAV87312.1	154 Y	PAEQYLQEK	0.667	unsp	YES
#					
# AAV87312.1	187 S	CKRFSELAN	0.956	unsp	YES
# AAV87312.1	187 S	CKRFSELAN	0.565	PKA	YES
#					
# AAV87312.1	200 Y	WKRLYMEVF	0.520	EGFR	YES
#					
# AAV87312.1	206 Y	EVFEYTRPM	0.502	unsp	YES
#					
# AAV87312.1	226 Y	NPEEYEHPN	0.962	unsp	YES
# AAV87312.1	226 Y	NPEEYEHPN	0.553	EGFR	YES
#					
# AAV87312.1	254 Y	AEHFYSNPA	0.950	unsp	YES
# AAV87312.1	254 Y	AEHFYSNPA	0.536	EGFR	YES
#					
# AAV87312.1	269 Y	NMLYYDTIE	0.566	unsp	YES

#						
# AAV87312.1	271 T	LYYDTIEDA	0.708	unsp	YES	
#						
# AAV87312.1	295 Y	HSGIYTDEW	0.546	unsp	YES	
#						
# AAV87312.1	296 T	SGIYTDEWI	0.582	CKII	YES	
#						
# AAV87312.1	301 Y	DEWIYIESP	0.973	unsp	YES	
# AAV87312.1	301 Y	DEWIYIESP	0.531	EGFR	YES	
# AAV87312.1	301 Y	DEWIYIESP	0.519	SRC	YES	
#						
# AAV87312.1	325 T	IIENTRDST	0.792	unsp	YES	
#						
# AAV87312.1	328 S	NTRDSTFVF	0.902	unsp	YES	
# AAV87312.1	328 S	NTRDSTFVF	0.573	PKA	YES	
#						
# AAV87312.1	336 S	FMEGSEDAY	0.526	CKII	YES	
#						
# AAV87312.1	340 Y	SEDAYVGYM	0.984	unsp	YES	
#						
# AAV87312.1	345 T	VGYMTIRFN	0.717	PKC	YES	
# AAV87312.1	345 T	VGYMTIRFN	0.601	unsp	YES	
#						
# AAV87312.1	382 T	IIRSTCTVG	0.558	PKC	YES	
#						
# AAV87312.1	384 T	RSTCTVGSA	0.783	PKC	YES	
#						
# AAV87312.1	399 T	GACPTIKHC	0.681	PKC	YES	
#						
# AAV87312.1	406 S	HCNISDCEN	0.937	unsp	YES	
# AAV87312.1	406 S	HCNISDCEN	0.562	CKII	YES	
# AAV87312.1	406 S	HCNISDCEN	0.558	PKA	YES	
#						
# AAV87312.1	423 Y	AQGIYEDNE	0.931	unsp	YES	
#						
# AAV87312.1	487 Y	EVKAYANPT	0.808	unsp	YES	
#						
# AAV87312.1	491 T	YANPTVVRC	0.626	PKC	YES	
#						
# AAV87312.1	521 Y	ENKIYANNF	0.929	unsp	YES	
# AAV87312.1	521 Y	ENKIYANNF	0.518	INSR	YES	
#						
# AAV87312.1	532 S	VWITSNSDP	0.813	unsp	YES	
#						
# AAV87312.1	537 T	NSDPTIRGN	0.765	unsp	YES	
# AAV87312.1	537 T	NSDPTIRGN	0.672	PKC	YES	
#						
# AAV87312.1	542 S	IRGNSIFNG	0.893	unsp	YES	
# AAV87312.1	542 S	IRGNSIFNG	0.777	PKA	YES	
#						
# AAV87312.1	567 Y	GNDIYGNAL	0.939	unsp	YES	
# AAV87312.1	567 Y	GNDIYGNAL	0.587	INSR	YES	
# AAV87312.1	567 Y	GNDIYGNAL	0.548	EGFR	YES	
#						
# AAV87312.1	580 S	IRTNSCPIV	0.732	PKA	YES	
#						
# AAV87312.1	613 Y	ENEVYSNTL	0.974	unsp	YES	
# AAV87312.1	613 Y	ENEVYSNTL	0.518	INSR	YES	
#						
# AAV87312.1	616 T	VYSNTLAGV	0.533	CKI	YES	
#						
# AAV87312.1	623 T	GVWVTTGST	0.747	PKC	YES	
#						
# AAV87312.1	627 T	TTGSTPVLR	0.647	cdk5	YES	
# AAV87312.1	627 T	TTGSTPVLR	0.536	p38MAPK	YES	
#						

DNEIFDNAMAGVWIKTDSNPTLRRNKIHGDRGGICIFNGGRGLLEENDI	#	750
FRNAQAGVLISTNSHPILRKNRIFDGFAAGIEITNHATATLEGNQIFNNR	#	800
FGGLFLASGVNVTMKDNKIMNNQDAIEKAVSRGQCLYKISSYTSYPMHDF	#	850
YRCHTCNTTDRNAICVNCIKKCHQGHVEDFIRHDRFFCDCGAGTLSNPCT	#	900
LASEPTHDTDTLYDSAPPIESNTLQHN	#	950
%1 ..S.....S.....	#	50
%1S.....S...S...	#	100
%1T....T..T.S....STS.....S.S...S...	#	150
%1 ...Y.....S.....Y	#	200
%1Y.....Y	#	250
%1 ...Y.....Y.T.....YT....	#	300
%1 Y.....T.S.....S...Y....T....	#	350
%1T.T.....T.	#	400
%1S.....Y	#	450
%1Y...T.....	#	500
%1Y.....S...T...S.....	#	550
%1Y.....S.....	#	600
%1Y..T....T...T.....S.....	#	650
%1Y.....S.....	#	700
%1T.....	#	750
%1S.....T.....	#	800
%1T.....S.....SS..SY....	#	850
%1T.....S...T	#	900
%1 ..S..T....T.Y.S.....		

36
37

38 **Supplementary Table 4. Mass spectrometry results (phosphorylation sites).**

39

NC-FBXO11-293T					
Position	Target	Modification	Classification	Highest Peptide Confidence	Sequence Motif
140	S	Phospho	Post-translational	High	AKRARAVsGKSQDL
143	S	Phospho	Post-translational	High	ARVSGKsQDLSAA
147	S	Phospho	Post-translational	High	GKSQDLsAAPAEQ
542	S	Phospho	Post-translational	High	PTIRGNsIFNGNQ
841	S	Phospho	Post-translational	High	CLYKISsYTSYPM
NDR1-FBXO11-293T					
Position	Target	Modification	Classification	Highest Peptide Confidence	Sequence Motif
140	S	Phospho	Post-translational	High	AKRARAVsGKSQDL
143	S	Phospho	Post-translational	High	ARVSGKsQDLSAA
147	S	Phospho	Post-translational	High	GKSQDLsAAPAEQ
187	S	Phospho	Post-translational	High	CVCKRFsELANDP

40

41

42 **Supplementary Table 5. NetPhos3.1 predicts phosphorylation sites on β-catenin by NDR1 (Score > 0.5).**

43

# Sequence	# x	Context	Score	Kinase	Answer
# CAA61107.1	3 T	--MATQADL	0.565	DNAPK	YES
# CAA61107.1	23 S	KAAVSHWQQ	0.749	PKC	YES
# CAA61107.1	23 S	KAAVSHWQQ	0.654	unsp	YES
# CAA61107.1	30 Y	QQQSYLDSG	0.815	unsp	YES
# CAA61107.1	33 S	SYLDSGIHS	0.564	PKC	YES
# CAA61107.1	37 S	SGIHSAGATT	0.525	PKA	YES
# CAA61107.1	40 T	HSGATTTAP	0.806	PKC	YES
# CAA61107.1	41 T	SGATTTAPS	0.766	unsp	YES
# CAA61107.1	41 T	SGATTTAPS	0.507	PKC	YES
# CAA61107.1	45 S	TTAPSLSGK	0.838	unsp	YES
# CAA61107.1	45 S	TTAPSLSGK	0.600	CKI	YES
# CAA61107.1	45 S	TTAPSLSGK	0.572	PKC	YES
# CAA61107.1	47 S	APSLSGKGN	0.995	unsp	YES
# CAA61107.1	47 S	APSLSGKGN	0.664	PKC	YES
# CAA61107.1	47 S	APSLSGKGN	0.605	CKI	YES
# CAA61107.1	59 T	EDVDTSQVL	0.542	CKII	YES
# CAA61107.1	60 S	DVDTSQVLY	0.665	ATM	YES
# CAA61107.1	60 S	DVDTSQVLY	0.597	DNAPK	YES
# CAA61107.1	60 S	DVDTSQVLY	0.512	CKII	YES
# CAA61107.1	71 S	EQGFSQSFT	0.561	DNAPK	YES
# CAA61107.1	71 S	EQGFSQSFT	0.557	ATM	YES
# CAA61107.1	71 S	EQGFSQSFT	0.525	cdc2	YES
# CAA61107.1	73 S	GFSQSFTQE	0.504	cdc2	YES
# CAA61107.1	73 S	GFSQSFTQE	0.500	PKC	YES
# CAA61107.1	75 T	SQSFTQEQQV	0.556	DNAPK	YES
# CAA61107.1	86 Y	IDGQYAMTR	0.540	unsp	YES
# CAA61107.1	89 T	QYAMTRAQR	0.589	PKC	YES
# CAA61107.1	102 T	MFPETLDEG	0.694	unsp	YES
# CAA61107.1	102 T	MFPETLDEG	0.558	CKII	YES
# CAA61107.1	111 S	MQIPSTQFD	0.572	cdc2	YES
# CAA61107.1	112 T	QIPSTQFDA	0.511	ATM	YES
# CAA61107.1	129 S	LAEPSQMLK	0.589	DNAPK	YES
# CAA61107.1	179 S	VHQLSKKEA	0.997	unsp	YES
# CAA61107.1	179 S	VHQLSKKEA	0.780	PKC	YES
# CAA61107.1	184 S	KKEASRHA	0.848	unsp	YES
# CAA61107.1	191 S	AIMRSPQM	0.629	cdk5	YES

# CAA61107.1	205 T	TMQNTNDVE	0.515	CKII	YES
#					
# CAA61107.1	210 T	NDVETARCT	0.768	unsp	YES
#					
# CAA61107.1	217 T	CTAGTLHNL	0.554	PKC	YES
#					
# CAA61107.1	222 S	LHNLSHHRE	0.937	unsp	YES
#					
# CAA61107.1	234 S	AIFKSGGIP	0.537	PKA	YES
#					
# CAA61107.1	246 S	KMLGSPVDS	0.979	unsp	YES
# CAA61107.1	246 S	KMLGSPVDS	0.534	p38MAPK	YES
# CAA61107.1	246 S	KMLGSPVDS	0.514	GSK3	YES
#					
# CAA61107.1	258 T	YAITTLHNL	0.717	unsp	YES
#					
# CAA61107.1	298 T	LAITTDCLO	0.536	CKII	YES
#					
# CAA61107.1	311 S	GNQESKLII	0.537	cdc2	YES
#					
# CAA61107.1	330 T	NIMRTTYYE	0.636	PKC	YES
#					
# CAA61107.1	339 T	KLLWTTSRV	0.558	PKC	YES
# CAA61107.1	339 T	KLLWTTSRV	0.500	cdc2	YES
#					
# CAA61107.1	340 T	LLWTTSRVL	0.870	unsp	YES
# CAA61107.1	340 T	LLWTTSRVL	0.638	PKC	YES
#					
# CAA61107.1	352 S	SVCSSNKPA	0.750	PKC	YES
#					
# CAA61107.1	374 S	LTDPSQRLV	0.615	DNAPK	YES
# CAA61107.1	374 S	LTDPSQRLV	0.507	ATM	YES
#					
# CAA61107.1	384 T	NCLWTLRNL	0.545	PKC	YES
#					
# CAA61107.1	389 S	LRNLSDAAT	0.988	unsp	YES
# CAA61107.1	389 S	LRNLSDAAT	0.708	PKA	YES
#					
# CAA61107.1	393 T	SDAATKQEG	0.546	CKII	YES
#					
# CAA61107.1	411 S	QLLGSDDIN	0.522	cdc2	YES
#					
# CAA61107.1	432 Y	TCNNYKNKM	0.549	unsp	YES
#					
# CAA61107.1	472 T	LRHLTSRHQ	0.946	unsp	YES
#					
# CAA61107.1	547 T	AHQDTQRRT	0.973	unsp	YES
#					
# CAA61107.1	552 S	QRRTSMGGT	0.998	unsp	YES
# CAA61107.1	552 S	QRRTSMGGT	0.714	PKA	YES
#					
# CAA61107.1	556 T	SMGGTQQQF	0.567	PKC	YES
# CAA61107.1	556 T	SMGGTQQQF	0.549	DNAPK	YES
#					
# CAA61107.1	605 S	QLLYSPIEN	0.957	unsp	YES
# CAA61107.1	605 S	QLLYSPIEN	0.525	p38MAPK	YES
#					
# CAA61107.1	646 S	ELLHSRNEG	0.991	unsp	YES
#					
# CAA61107.1	653 T	EGVATYAAA	0.502	PKC	YES
#					
# CAA61107.1	663 S	LFRMSEDKP	0.718	unsp	YES
#					
# CAA61107.1	670 Y	KPQDYKKRL	0.527	INSR	YES
#					
# CAA61107.1	675 S	KKRLSVELT	0.997	unsp	YES

# CAA61107.1	675 S	KKRLSVELT	0.718	PKA	YES
#					
# CAA61107.1	681 S	ELTSSLFRT	0.514	cdc2	YES
#					
# CAA61107.1	715 S	QDDPSYRSF	0.992	unsp	YES
# CAA61107.1	715 S	QDDPSYRSF	0.874	PKC	YES
#					
# CAA61107.1	716 Y	DDPSYRSFH	0.904	unsp	YES
# CAA61107.1	716 Y	DDPSYRSFH	0.522	INSR	YES
#					
# CAA61107.1	718 S	PSYRSFHSG	0.642	unsp	YES
#					
# CAA61107.1	724 Y	HSGGYGQDA	0.504	INSR	YES
<hr/>					
MATQADLMELDMAMEPDRKAAVSHWQQQSYLDGSIHSGATTAPSLSKG #	50				
NPEEEDVDTSQLYEWEQGFSQSFTQEQUADIDGQYAMTRAQRVRAAMFP #	100				
ETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLLINYQDDAELAT #	150				
RAIPELTKLNDDEDQVVVNKAAMVHQLSKKEASRHAIMRSPQMVAIVR #	200				
TMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDS #	250				
VLFYAITTLHNLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDC #	300				
LQILAYGNQESKLIILASGGPQALVNIMRTTYEKLLWTTSRVLKVLSVC #	350				
SSNKPAIVEAGGMQALGLHLDPSQRLVQNCLWTLRNLSDAATKQEGMEG #	400				
LLGTLVQLLGSDDINVVTCAAGILSNLTCCNYKNKMMVCQVGIEALVRT #	450				
VLRAGDREDITEPAICALRHLTSRHQEAEAMAQNARLHYGLPVVKLLHP #	500				
PSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRR #	550				
TSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFV #	600				
QLLYSPIENIQRVAAGVLCELAQDKEAAEAIAEAGATAPLTELLHSRNEG #	650				
VATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMMAWNETADLGLDI #	700				
GAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGHHPGADYPV #	750				
DGLPDLGHAQDLMGDPGDSNQLAWFDTDL #	800				
<hr/>					
%1 ..T.....S.....Y..S...S..TT...S.S... #	50				
%1TS.....S.S.T.....Y..T..... #	100				
%1 .T.....ST.....S..... #	150				
%1S...S....S..... #	200				
%1T....T....T....S.....S.... #	250				
%1T.....T.....T.. #	300				
%1S.....T.....TT..... #	350				
%1 ..S.....S.....T....S..T..... #	400				
%1S.....Y..... #	450				
%1T..... #	500				
%1T... #	550				
%1 ..S..T..... #	600				
%1S.....S... #	650				
%1 ..T.....S.....Y....S..... #	700				
%1SY.S....Y..... #	750				
%1					

44

45